Initial digest — MTOR receipt

what this node claims

Initial digest — MTOR

AlphaFold v6 prediction landed for **MTOR** (Mechanistic target of rapamycin). UniProt accession: `P42345`. Lane: `longevity`. Mean per-residue pLDDT: **77.97**. Selective TORC1 inhibitor (rapalog-class) wedge — mTORC...

Open source surface

vertical proof spine

evidence / risk instrument

39%

thin proof

low debt pressure 29%

28%structuredebt

pLDDT pending

55%evidencethin

grade C

0%gatesdebt

0/5 gates

100%riskstrong

0 hard flags

22%exportdebt

no export

33%lineagedebt

incomplete spine

proof completeness

33% missing target, alphafold_metric, candidate, export

01 target
02 fold
03 alphafold metric
04 candidate
05 finding
06 export

Metrics and receipt inputs

confidence: 0.6
evidence refs: 1

AlphaFold metrics visual

Confident backbone model

78.0

2549 residues / min 23.27 / max 94.56 / source alphafold db

Very high 10.7% 272 residues / >=90

Confident 71.5% 1822 residues / 70-89

Low 8.0% 204 residues / 50-69

Very low 9.8% 251 residues / <50

usable fold context with explicit model-confidence limits

Near-complete coverage / observed 2549 of 2549 residues.

residues 285-358 / mean 36.26
residues 2423-2494 / mean 40.7
residues 1811-1871 / mean 39.08
residues 1219-1260 / mean 49.55

proof debt register

Visible limits, not hidden cleanup.

29%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

high low evidence grade attach graded finding with source-linked evidence

low computational-only status add independent evidence, challenge result, or witness review before strengthening

medium no candidate yet leave visible until a stronger public receipt resolves it

Initial digest — MTOR